Generate Biomedicines, Inc. (NASDAQ: GENB) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Generate Biomedicines, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.84, Generate Biomedicines, Inc. trades at 45.5x sales and 3.3x book value. Over the last twelve months it generated about $28M of revenue and a net loss of $306M. It runs a gross margin of 88.3%, an operating margin of -1030.5% and a net margin of -963.8%. It shows return on equity of -146.1%, return on invested capital of -63.0% and a free cash flow yield of -19.7%. On the balance sheet: a debt-to-equity ratio of 0.20 and a current ratio of 5.01. Over the past 52 weeks the share price ranged from $9.73 to $22.67, with a beta of -0.14.
Generate Biomedicines, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.